Is there really a first FDA-approved treatment for Sanfilippo syndrome?

Fayuvi is the first FDA-approved option for pediatric MPS IIIA — a one-time gene therapy, and an important early milestone rather than a guaranteed cure.

Yes. Nature reported on Oct. 5 that the FDA approved Ultragenyx's rebisufligene etisparvovec (Fayuvi) for pediatric patients with Sanfilippo syndrome type A, also called MPS IIIA. Until now, families facing this diagnosis had no approved treatment at all — only supportive care. This page is our complete, plain-English guide to what the approval means.

What is Sanfilippo syndrome type A?

Sanfilippo syndrome is a rare inherited disorder. Children with type A are born missing a working copy of the SGSH gene, which makes an enzyme that breaks down a cellular waste product called heparan sulfate. Without that enzyme, the waste piles up inside cells — especially in the brain and nervous system. Symptoms usually appear in early childhood: slowed development, speech delays, behavior changes, and eventually severe neurological decline. It is relentlessly progressive, and until this approval there was no treatment that addressed the underlying cause.

What does Fayuvi actually do?

Fayuvi is a gene therapy, which means it tries to fix the problem at its source. In a one-time intravenous infusion, patients receive a working copy of the SGSH gene carried by a harmless engineered virus (an AAV vector) that acts as a delivery truck. Once inside the patient's cells, the new gene instructs them to start producing the missing enzyme themselves. The idea is simple to state and extraordinarily hard to execute: give the body the instructions it was born without, so it can clear the waste buildup on its own.

What does "FDA approved" actually mean here?

Approval means the FDA reviewed the trial data and concluded the therapy's benefits outweigh its risks for the approved group — pediatric patients with MPS IIIA. That is a genuine first: no drug had ever cleared that bar for this disease. But "approved" is not the same as "proven cure." The trials measured biological effects — enzyme activity and biomarker levels — and the evidence on how much, and for how long, it changes children's daily lives will keep developing now that the therapy is in wider use. Think of it as the end of the beginning: the first real option, with long-term follow-up still to come.

What do families usually do next?

Only a specialist center can assess an individual child, so the practical next step is a referral to a team experienced in lysosomal storage disorders. Questions families typically bring to that appointment: is my child eligible (age, disease stage, and prior treatments all matter)? What benefit can we realistically expect, and on what timeline? What are the known risks and side effects of the infusion? What monitoring and follow-up does the treatment require? And what does insurance cover? Bring records, bring a list, and bring someone to take notes — these appointments carry a lot of information.

What to watch from here

Two things matter going forward. First, durability: gene therapies are designed as one-time treatments, but how long the effect lasts in real children is the question every follow-up study will try to answer. Second, the other Sanfilippo types — B, C, and D, caused by different missing enzymes — still have no approved treatment, so research continues there too. Pro tip: when you see headlines about new approvals, skip the hype and go to the primary source — the FDA's announcement and the published trial data tell you what was actually shown, and what wasn't.